Related Experiment Video
Updated: Jul 18, 2026
10:28
An Injectable and Drug-loaded Supramolecular Hydrogel for Local Catheter Injection into the Pig Heart
Published on: June 7, 2015
Gentamicin extended release from an injectable polymeric implant.
Michal Y Krasko1, Jacob Golenser, Abraham Nyska
1Department of Medicinal Chemistry and Natural Products, School of Pharmacy, The Hebrew University of Jerusalem, 91120 Jerusalem, Israel.
Summary
This study introduces a new injectable polymer device for controlled gentamicin sulfate release, showing promise for treating osteomyelitis (bone infection) with sustained antibiotic delivery and minimal inflammation in animal models.
Area of Science:
- Biomaterials Science
- Infectious Diseases
- Drug Delivery Systems
Background:
- Osteomyelitis treatment often involves invasive methods like intravenous gentamicin or antibiotic-loaded bone cements.
- There is a need for advanced drug delivery systems offering sustained and localized antibiotic release for bone infections.
Purpose of the Study:
- To evaluate biodegradable injectable gelling polymeric devices for controlled gentamicin sulfate release.
- To assess the efficacy and safety of these devices in treating invasive bacterial infections, specifically osteomyelitis.
Main Methods:
- Gentamicin sulfate was incorporated into poly(sebacic-co-ricinoleic-ester-anhydride) P(SA-RA) paste (10-20% w/w).
- In vitro gentamicin release, antibacterial activity against Staphylococcus aureus, formulation stability, and in vivo toxicity in rats were evaluated.
- A rat model of osteomyelitis was used for preliminary efficacy assessment.
Main Results:
- The P(SA-RA) formulations demonstrated constant gentamicin sulfate release for over 28 days.
- Formulations were stable after gamma-irradiation sterilization and long-term freezing.
- Subcutaneous implantation in rats showed no surrounding tissue inflammation, and a preliminary study indicated a positive effect on established osteomyelitis.
Conclusions:
- Poly(sebacic-co-ricinoleic-ester-anhydride) 3:7 loaded with 10%-20% gentamicin sulfate shows potential as an injectable biodegradable device.
- This formulation may offer an effective in situ treatment for Staphylococcus aureus-induced osteomyelitis.
Related Concept Videos
01:28Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...